

Clinical Reports



Cibele Maria Lage Siqueira^a 🛛 🖂 | Rosa Yana Jerdaqui Baalbaki^b 💿

^a Unversidade Federal do Norte – Tocantins, Brasil – Researcher at the Unversity of Minas Gerais

^b Master in Dentistry – Unicsul – São Paulo, Brasil – Master in Neural Therapy – University of Barcelona

Abstract

1

Clinical case patient SFM code: 7612, date of birth September 9, 1978. Patient starts treatment on November 25, 2019, had already had other dental treatments, still complaining of cervical reflex pain, in addition to facial tension, headaches, complaints of tiredness, fatigue, malocclusion, verticalization of the divergent buccal void, inflamed microsystems with stagnation and blood ischemia, oral dysbiosis, sinusitis recurrence and some significant autoimmune systemic changes. Dental treatment was multidisciplinary and aimed at reducing inflammation processes, improving systemic microcirculation, improving occlusion, better load distribution, improving oral biocybernetics together with the body axes, trying to minimize the histamine effects released that lead to triggers of conditions autoimmune. The treatment consisted of dental procedures with endodontics and extraction of structures incompatible with the patient's health, biochemical evaluation of markers, medical follow-up. Methodology used were laboratory blood tests (hemogram as a reference and auxiliary tests to confirm the clinical finding, panoramic view, x-ray), neural therapy procedures, tooth extraction, endodontics, ozone therapy. Results obtained were significant in the circulatory system, improvements in the excretion system, hepatic system, improvements in the glycemic condition. Conclusion The patient had a significant gain in quality of life and is still undergoing treatment because some blood markers need long-term changes and cannot be worked on all at once.

Keywords: Exodontia, endodontics, blood markers

1. Clinical Report

Patient SFM, with code 7612, born on September 9, 1978, initiated their treatment on November 25, 2019. They had previously undergone other dental treatments and complained of referred cervical and lumbar pain, facial tension, headaches, recurrent sinusitis, fatigue, and exhaustion. After a clinical and imaging examination, malocclusion, divergence of the oral cavity, inflamed microsystems with stagnation and blood ischemia, oral dysbiosis, recurrent sinusitis, and some significant autoimmune systemic alterations were identified.

The patient reported traumas from previous dental treatments, which is why we proposed minimal multidisciplinary interventions. After obtaining their consent, treatment began with the request for laboratory tests, panoramic and periapical radiographs of all teeth to elucidate the clinical examination results. A Huneke test was performed, which tested positive for alterations in the molars of teeth 18, 16, 48, 28, and 37.

15

2 3 4

5

6

7

8

9



SCA FLAND MERCENSION Código:7612 / Nasc:09/09/1978 Dr(a): ROSA YANA BAALBAKI Data do exame: 21/11/2019




Figure 1 Panoramic X-ray of Patient SFM

The blue arrow indicates an area with lesions at the apex of the root canal of tooth 37, and the yellow arrow can be observed both in the panoramic X-ray and in the visualization of the oral mucosa, confirming the indication of recurrent sinusitis and a dysbiosis process. Through imaging exams, the endodontic lesion of tooth 37 and the mispositioning of tooth 28, both identified as positive in the Huneke test, were confirmed. Extraction of tooth 28 was recommended, as well as endodontic treatment for tooth 37. Vestibular and lingual applications were initiated in the regions of positive teeth (areas of 3rd molars, incisors, centrals, 36, 37, 27, 28).

In the endodontic retreatment of tooth 37, performed with ozone application in the canals, a fractured file and prefabricated metallic core were successfully removed. The patient wished to retain the anatomical piece, and after a few days, procaine was applied again to the affected areas.



31 The orange arrow shows the lesion. In late 2019 until 2022, many healthcare procedures were suspended or reduced 32 due to the pandemic, causing the patient to postpone the extraction and endodontic treatment. The patient underwent neural 33 therapy with the application of 0.7% Procaine Hydrochloride at specific points on the head and neck, as clinically indicated 34 during the dental treatment.

Figure 2 Periapical X-ray of Patient SFM

35



³⁶ 37

Figure 3 Periapical X-ray of the patient after endodontic treatment

38 In an effort to preserve teeth 18, 28, and 48 (at the patient's request), resin restorations were redone on December 4, 39 2019, December 11, 2019, and January 15, 2020. However, the patient still exhibited clinical signs of discomfort in these teeth 40 and a positive Huneke test even after the restorations were replaced. On March 6, 2020, a full molding and assembly of study 41 models in an A.S.A (semi-adjustable articulator) revealed premature contact occurring between tooth 28 and 37 during 42 mandibular excursive movements. Extractions of teeth 18 and 48 were initiated on March 5, 2021, and extraction of tooth 28

on June 11, 2021. In June 2022, it was decided to perform endodontic retreatment of tooth 37, with removal of the metallic core and fractured file. A full ceramic crown with contact point and satisfactory occlusion was placed, and there were no longer any positive Huneke test results for this tooth.

In January 2022, the patient presented with a COVID-19 infection.

Throughout the entire duration, the patient's clinical condition was monitored through blood marker tests. It was decided to follow the patient for at least an additional 3.5 years, investigating their markers even after the completion of dental treatment.

Reference values will be adopted for the patient according to current laboratory literature, but a more detailed analysis will be performed using quartiles from the Gaussian curve to visualize and report any biochemical alterations in the results.

Table 1 Reference Values Table: Red Section

Complete Blood Count	
Red Blood Cells	3,800,000 to 5,200,000/mm3
Hemoglobin	12.0 to 16.0 g/dl
Hematocrit	35.0 to 47.0%
Mean Corpuscular Volume (MCV)	80.0 to 100.0 fl
Mean Corpuscular Hemoglobin (MCH)	26.0 to 34.0 pg
Mean Corpuscular Hemoglobin Concentration (MCHC)	32.0 to 36.0%
Red Cell Distribution Width (RDW)	11.6 to 14.6%

Table 2 Reference Values Table: White Blood Cells

White Blood Cells	
Total Leukocyte Count	4,000 to 11,000 /mm3
Bands	40 to 80%, 2,000 to 7,000/mm3
Segmented	67%, 4,221/mm3
Eosinophils	1 to 6%, 2 to 500/mm3
Basophils	0 to 2%, 0 to 100/mm3
Monocytes	2 to 10%, 200 to 1,000/mm3
Lymphocytes	20 to 40%, 1,000 to 3,000/mm3
Reactive Lymphocytes	0%, 0/mm3
Other Hematology Findings: Marked anisocytosis,	
microcytosis, and hypochromia. Rare macrocytes. Mild	0%, 0/mm3
poikilocytosis and slight polychromasia	
Platelets	140,000 to 450,000/mm3

The medical literature tells us that there are no acceptable values for heavy metals, proposing a retrograde contamination limit for acute manifestation. Therefore, tests were requested, and the gradual biological terrain cleansing of the patient was initiated.

- 1.1 Blood Marker Results:
 - 1.1.1. In the clinical examination in 2019 during the anamnesis, pale eyelid conjunctiva and oral mucosa were observed, slightly whitish, lacking vitality, and with mild ischemia, suggesting anemia.
 - 1.1.2. In November 2020, the first extraction of the wisdom teeth was performed.
 - 1.1.3. In the clinical examination in 2020 during the anamnesis, the eyelid conjunctiva and oral mucosa were slightly whitish, lacking vitality, with mild ischemia, but there is no indication of anemia.

		Table 3 Table of Marker Results af		-	ervention		
	Value on 11/20/ 2020	Complete	Blood Cour Values before applicat ion on 02/21/ 2022	nt Values on 04/22/202 2 after applicatio n		Values after COVID on 05/15/ 2022	Values on 06/23/ 2022
Red Blood Cells	4.43 x 10^6 /μL	Still in the first quartile of the Gaussian curve, indicative of tissue oxygenation recovery and peripheral microcirculation	4.22 x 10^6 /μL	4.51 x 10^6 /μL	Interfering Field	4.44 x 10^6 /μL	4.56 x 10^6 /μL
Hemoglo bin Hematocr	13.6 g/dL 41.4%		13.4 g/dL 39.0%	14.0 g/dL 41.3%		13.6 g/dL 41.3%	13.9 g/dL 41.0%
it	93.3 fL	The mean corpuscular volume is in the third quartile of the curve, still within the normal range. However, it is not within the desirable range, indicating that the spatial configuration of the mean corpuscular volume was larger than desirable. Therefore, oxygenation in the capillaries and oxygen transport are somewhat compromised. Suspicions of heavy metal intoxication and an inflammatory process were suggested.	92.5 fL	91.8 fL	Volume corpuscula r closer to the ideal	93 fL	90.5 fL
нсм	30.7pg	It falls within the ideal range, suggesting good iron absorption, not dependent on Methylcobalamin.	31.8 pg	31.1 pg		30.6 pg	30.7 pg
CHCM	32.9 g/dL		34.3 g/dL	33.9 g/dL		32.9 g/dL	33.9 g/dL
RDW	12.9%	The erythrocyte sedimentation rate is within the normal range; however, it is lower.	13.8%	13.2%		13.8%	13%
	Although	ood cell series, we observe a chronic the patient's results fall within refere with the patient's clinical his	ence values	, the quartiles	show clinical		
Leukocyt es	100% 5.070/ μL		100% 6100/μL	100 % 6.240 /μL		100 % 5610 /μL	100 % 6100 /μL
Neutroph ils	59,3% 3.007/ μL		67,7% 4130/μL	55,4 % 3.457 /μL		61,5 % 3.457 /μL	67,7 % 4.130 /μL
Eosinophi Is:	1,5% 76/μL		1,3% 79//μL	0,9 % 56 /μL	Allergenic load decreases	1,7 % 95 /μL	1,3 % 79 /μL
Basophils							

	0,3%	0,5%	1,8 % 112		0,4 % 22	0,5 %
	15/μL	31//µL	/μL		/μL	31/µL
	31,4%	24,4%		Autoimmu		24,4 %
Lymphoc	1.592	1488//µ	33,7 %	ne	29,7 %	1488
ytes	/μL	L	2.103 /μL	condition	1666 /μL	/µL
Monocyt	7,5%	6,1%37	8,2 % 512		6,7 %	6,1%
es	380	2//μL	/μL		376 /μL d	372
	/μL					/μL


89 It can be observed that there is an improvement in the microcirculatory process despite the emergence of other 90 symptoms. The patient experienced a reduction in allergens, a reduction in the dysbiotic condition, and improved visual 91 appearance of the mucous membranes. During this initial period, the patient still had some restrictions on achieving better 92 dietary control. She was advised to undergo a food allergy test with the aim of reducing systemic inflammatory processes, 93 improving the control of mucus channels, and regulating systemic histamine release, all of which significantly contribute to the 94 treatment of autoimmune symptoms. It can be noted that the complete blood count was an excellent, low-cost, simple, 95 sensitive, and rapid biological marker in the diagnostic process, and other tests were requested mainly as laboratory evidence 96 to support the findings of the complete blood count. 97

98 Monitoring of lipid patterns, essential minerals, insulin response, and inflammatory factors was also carried out due to 99 the patient's clinical condition. Additionally, in-office evaluation of endodontic procedures was performed, followed by medical 100 monitoring. The results for minerals were quite homogeneous, such as Blood Zinc (73.02 µg/dL), Magnesium (2.0 mg/dL), 101 Sodium (140 mMol/L), Calcium (9.3 mg/dL), Potassium (3.9 mEq/L), and the observed alterations were not related to the 102 patient's mineral patterns. Ferritin (20.1 ng/mL), Vitamin C (8.2 mg/dL), Copper (83.9 µg/dL), Iron Metabolism; Iron (74 µg/dL), 103 Total Iron-Binding Capacity (250 µg/dL), Iron (324 µg/dL), Transferrin Saturation (23%). Reference values for serum iron and 104 other tests related to iron metabolism are standardized for samples collected up to 11:00 AM due to circadian rhythm 105 variations. Therefore, the observed hematopoietic alterations are related to sympathetic stimulation of the vegetative system 106 and autoeco-organization processes to achieve homeostasis, as per Burtis, CA; Ashwood, ER; Bruns, DE. Tietz Textbook of 107 Clinical Chemistry and Molecular Diagnosis. 4th Ed. Saint Louis: Elsevier Saunders, 2006; Soldin, SJ; Brugnara, C; Wong, EC, 108 Soldin, OP. Pediatric Reference Intervals. 7th Ed. Washington DC: AACCPress, 2011. Additionally, Methylmalonic Acid (0.10 109 μ mol/L) and Vitamin B-12 level of 455 pg/mL were observed.

111The patient has a more sympatholytic profile, experiencing constant stress, which was measured by salivary cortisol112levels. She also has an androgenic profile with levels within the normal range but in the third quartile of testosterone113production, which increases the severity and exacerbation of autoimmune pathologies. These include Basal Cortisol 21.0 µg/dL114measured in the morning, Calculated Free and Bioavailable Testosterone, Total Testosterone 59.0 ng/dL (elevated), Sex115Hormone-Binding Globulin (SHBG) 85.0 nmol/L, Free Testosterone 19.2 pmol/L, and Bioavailable Testosterone 12.9 ng/dL.

116 117

118 2. Results



With a Hemoglobin A1c (HbA1c) result of 5.3% and assessment of homo and beta insulin activity, possible causes of cellular
dehydration and low enzymatic activity due to the biological terrain were identified. Reference: American Diabetes Association. Standards
of Medical Care in Diabetes. Diabetes Care. 2017. As the patient's energy gain and disposition improved, there was a reduction in dysbiosis
processes.








Figure 9 Total bilirubin, direct and indirect bilirubin

Proteína C Reativa	Ultra sensível	0.09 mg/dl		(Vida Intervala da Deferânzia Al-	
riotoina o neativa	Grana Gonorver	0,08 mg/dL		(Vide Intervalo de Referência Aba (Mate (Método: Imunoturb	rial: Soro)
Tabela de Referência - F	Proteína C Reativa Ultra ser	nsivel		Versioners, Internetioners	
		Valor de	referência:		
Baixo risco <0,1mg/dL	Médio Risco 0,1 a 0,2mg/dL	Alto Risco >0,2mg/dL	Muito alto risco >1mg/dL	Doenças Inflamatórias Fase Aguda >=1mg/dL	
Gráfico de Histórico					
_ 0,1	• • •				
(10 0,1) (10 0,1)					
20 0.1 20 0.1				0.08	
æ 0,0	8 -				
	21/02/2022 09:18		ala	23/05/2022 08:39	
Obs.:Para obter o resultado					
Nota 1: Na vigência de proce	-			Association infonsione au impress umo um que	
podem interferir na dosagem				flamatórias, infecciosas ou imunes, uma vez que e	estas
Nota 3: Não se recomenda o cardiovascular global e em o		cação de risco em pacient	es com doença aterosclere	itica manifesta ou subclínica, com alto risco	
Referência Bibliográfica:					
	ologic explanation for "high- leira de Dislipidemias e Pre	sensitivity" C- reactive prot venção da Aterosclerose -	ein and "low-grade" inflam 2017; Arq Bras Cardiol 20	mation. Arthritis Care Res. 2010; 62 (4):442. 17; 109(2Supl.1):1-76.	
Liberado por: Rogerio Alex dos Sar					
Responsável: Dra. Dalva Margaret	h Valente Gomes - CRM - RJ 525	25304			
	Fic	www. 10 Liltra com			
	1.18	gure to Oltra-sens	sitive C-reactive p	protein	
	1 18		sitive C-reactive p		
mbo Sanguíneo I: Sangue Total)	- 1 <u>8</u>	1,44 µg/dL	·	VIOTEIN (Vide Intervalo de Refr do: ICP-MS (Plasma Indutivamente Acoplado ao Espectr	
	1 18		·	(Vide Intervalo de Refe	
I: Sangue Total)	ncia - Chumbo Sanguíne	1,44 µg/dL	·	(Vide Intervalo de Refe	
I: Sangue Total)		1,44 µg/dL	(Métc	(Vide Intervalo de Refr do: ICP-MS (Plasma Indutivamente Acoplado ao Espectr	
I: Sangue Total)	ncia - Chumbo Sanguíne	1,44 µg/dL	(Méte Notas: Valor IBMf	(Vide Intervalo de Refr do: ICP-MS (Plasma Indutivamente Acoptado ao Espectr Valor de Referência: até 40,0 µg/dL IBMP: até 60,0 µg/dL	
I: Sangue Total)	ncia - Chumbo Sanguíne	1,44 µg/dL io	(Méto Notas: Valor IBMf Io laboratório de acordo	(Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acoptado ao Espectr Valor de Referência: até 40,0 µg/dL IBMP: até 60,0 µg/dL de Referência para pacientes não expostos. P: Índice Biológico Máximo Permitido (NR-7)	ômetro de
E Sangue Total)	ncia - Chumbo Sanguíne	1,44 µg/dL No Jenvolvida e validada pel	(Méto Notas: Valor IBMf Io laboratório de acordo	(Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acoptado ao Espectr Valor de Referência: até 40.0 µg/dL IBMP: até 60.0 µg/dL de Referência para pacientes não expostos. P: Índice Biológico Máximo Permitido (NR-7) com a RDC 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (26/02/20	ômetro de
I: Sangue Total)	ncia - Chumbo Sanguíne	1,44 µg/dL io	(Méto Notas: Valor IBMf Io laboratório de acordo	(Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acoptado ao Espectr Valor de Referência: até 40,0 µg/dL IBMP: até 60,0 µg/dL de Referência para pacientes não expostos. 2: Indice Biológico Máximo Permitido (NR-7) com a RDC 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (26/02/20 Infe Pacientes em hemodiálise	ómetro de
E Sangue Total) Tabela de Referê	ncia - Chumbo Sanguíne	1,44 µg/dL No Jenvolvida e validada pel	(Méto Notas: Valor IBMi Io laboratório de acordo	(Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acoptado ao Espectr Valor de Referência: até 40,0 µg/dL IBMP: até 60,0 µg/dL de Referência para pacientes não expostos. P: Indice Biológico Máximo Permitido (NR-7) com a RDC 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (26/02/20 Infe	ômetro de
t: Sangue Total) Tabela de Referê aggem de Alumínio angue	ncia - Chumbo Sanguíne Metodologia des	1,44 μg/dL o envolvida e validada pel L 3,50 μg/L	(Méic Notas: Valor IBM lo laboratório de acordo iberado por: Sheila Vaso	(Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acoptado ao Especte Valor de Referência: até 40,0 µg/dL IBMP: até 60,0 µg/dL de Referência para pacientes não expostos. P: Índice Biológico Máximo Permitido (NR-7) com a RDC 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (26/02/20 Infe Pacientes em hemodiálise (Resultados acima deste ve Portaria N.82/GM em 03/01 (Método: Espectrofotometria de Absorção Atômica com	ômetro de
t: Sangue Total) Tabela de Referê aggem de Alumínio angue	ncia - Chumbo Sanguíne Metodologia des	1,44 μg/dL ο envolvida e validada pel L 3,50 μg/L da pelo laboratório d	(Mété Notas: Valor IBM lo laboratório de acordo iberado por: Sheila Vaso e acordo com a RDO	(Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acoptado ao Espectr Valor de Referência: até 40,0 µg/dL IBMP: até 60,0 µg/dL de Referência para pacientes não expostos. 2: Indice Biológico Máximo Permitido (NR-7) com a RDC 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (26/02/20 Infe Pacientes em hemodiálise (Resultados acima deste va Portaria N.82/GM em 03/01	022 09:21 022 09:22 rior a 10 - até 30 alor, cons /2000 At a Corretor 2
E Sangue Total) Tabela de Referê aggem de Alumínio angue E Soro) Metodologia d	ncia - Chumbo Sanguíne Metodologia des	1,44 μg/dL o envolvida e validada pel L 3,50 μg/L da pelo laboratório d L	(Mété Notas: Valor IBM lo laboratório de acordo iberado por: Sheila Vaso e acordo com a RDO	(Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acoptado ao Espect Valor de Referência: até 40,0 µg/dL IBMP: até 60,0 µg/dL de Referência para pacientes não expostos. P: Indice Biológico Máximo Permitido (NR-7) com a RDC 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (26/02/20 Infe Pacientes em hemodiálise (Resultados acima deste va Portaria N.82/GM em 03/01 (Método: Espectrofotometria de Absorção Atômica com C 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (23/02/20	022 09:21 rior a 10 - até 30 Jor, cons /2000 AN a Corretor 3
t: Sangue Total) Tabela de Referê aggem de Alumínio angue	ncia - Chumbo Sanguíne Metodologia des	1,44 μg/dL ο envolvida e validada pel L 3,50 μg/L da pelo laboratório d	(Méte Notas: Valor IBMI lo laboratório de acordo iberado por: Sheila Vaso e acordo com a RDO iberado por: Sheila Vaso	(Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acoptado ao Espect Valor de Referência: até 40,0 µg/dL IBMP: até 60,0 µg/dL de Referência para pacientes não expostos. P: Indice Biológico Máximo Permitido (NR-7) com a RDC 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (26/02/20 Infe Pacientes em hemodiálise (Resultados acima deste va Portaria N.82/GM em 03/01 (Método: Espectrofotometria de Absorção Atômica com C 302 de 13/10/2005, Art. 5.5.5.1.	022 09:21 rior a 10 - até 30 Jor, cons /2000 AN a Corretor 3 022 09:0
E Sangue Total) Tabela de Referê agem de Alumínio angue E Soro) Metodologia d agem de Mercúrio	ncia - Chumbo Sanguíne Metodologia des	1,44 μg/dL o envolvida e validada pel L 3,50 μg/L da pelo laboratório d L	(Méte Notas: Valor IBM lo laboratório de acordo iberado por: Sheila Vaso e acordo com a RDO iberado por: Sheila Vaso	(Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acoptado ao Espect Valor de Referência: até 40,0 µg/dL IBMP: até 60,0 µg/dL de Referência para pacientes não expostos. P: Indice Biológico Máximo Permitido (NR-7) com a RDC 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (26/02/20 Infe Pacientes em hemodiálise (Resultados acima deste va Portaria N.82/GM em 03/01 (Método: Espectrofotometria de Absorção Atômica com C 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (23/02/20	022 09:21 rior a 10 - até 30 Jor, cons /2000 AN a Corretor 3 022 09:0
E Sangue Total) Tabela de Referê agem de Alumínio angue E Soro) Metodologia d agem de Mercúrio E Sangue Total)	ncia - Chumbo Sanguíne Metodologia des	1,44 μg/dL o envolvida e validada pel L 3,50 μg/L da pelo laboratório d L 0,18 μg/dL	(Méte Notas: Valor IBM lo laboratório de acordo iberado por: Sheila Vaso e acordo com a RDO iberado por: Sheila Vaso	(Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acopiado ao Espect Valor de Referência: até 40,0 µg/dL IBMP: até 60,0 µg/dL de Referência para pacientes não expostos. P: Indice Biológico Máximo Permitido (NR-7) com a RDC 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (26/02/20 Infe Pacientes em hemodiálise (Resultados acima deste va Portaria N.82/GM em 03/01 (Método: Espectrofotometria de Absorção Atômica com C 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (23/02/20 (Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acopiado ao Espect	022 09:21 rior a 10 - até 30 Jor, cons /2000 AN a Corretor 3 022 09:0
E Sangue Total) Tabela de Referê agem de Alumínio angue E Soro) Metodologia d agem de Mercúrio E Sangue Total)	ncia - Chumbo Sanguíne Metodologia des	1,44 μg/dL o envolvida e validada pel L 3,50 μg/L da pelo laboratório d L 0,18 μg/dL	(Méic Notas: Valor IBMI lo laboratório de acordo iberado por: Sheila Vaso e acordo com a RD(iberado por: Sheila Vaso (Méic Exposiçã	(Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acoplado ao Espect Valor de Referência: até 40,0 µg/dL IBMP: até 60,0 µg/dL de Referência para pacientes não expostos. P: Índice Biológico Máximo Permitido (NR-7) com a RDC 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (26/02/20 Pacientes em hemodiálise (Resultados acima deste ve Portaria N.82/GM em 03/01 (Método: Espectrofotometria de Absorção Atômica com C 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (23/02/20 (Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acoplado ao Espectr Até 1,0 µg/dL to a Mercúrio Orgânico: Maior que 5,0 µg/dL	022 09:21 rior a 10 - até 30 Jor, cons /2000 AN a Corretor 3 022 09:0
E Sangue Total) Tabela de Referê agem de Alumínio angue E Soro) Metodologia d agem de Mercúrio E Sangue Total)	ncia - Chumbo Sanguíne Metodologia des	1,44 μg/dL o envolvida e validada pel L 3,50 μg/L da pelo laboratório d L 0,18 μg/dL	(Méic Notas: Valor IBMI lo laboratório de acordo iberado por: Sheila Vaso e acordo com a RD(iberado por: Sheila Vaso (Méic Exposiçã	(Vide Intervalo de Referência: até 40,0 µg/dL IBMP: até 60,0 µg/dL de Referência para pacientes não expostos. 2: Indice Biológico Máximo Permitido (NR-7) com a RDC 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (26/02/20 Infe Pacientes em hemodiálise (Resultados acima deste va Portaria N.82/GM em 03/01 (Método: Espectrofotometria de Absorção Atômica com C 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (23/02/20 (Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acoplado ao Espectr	022 09:21 rior a 10 - até 30 Jor, cons /2000 AN a Corretor 3 022 09:0
E Sangue Total) Tabela de Referê agem de Alumínio angue E Soro) Metodologia d agem de Mercúrio E Sangue Total) Tabela de Referê	ncia - Chumbo Sanguíne Metodologia des esenvolvida e validad	1,44 μg/dL o envolvida e validada pel L 3,50 μg/L da pelo laboratório d L 0,18 μg/dL úrio	(Méx Notas: Valor IBM lo laboratório de acordo iberado por: Sheila Vaso iberado por: Sheila Vaso (Méx Exposição	(Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acoplado ao Espect Valor de Referência: até 40,0 µg/dL IBMP: até 60,0 µg/dL de Referência para pacientes não expostos. P: Índice Biológico Máximo Permitido (NR-7) com a RDC 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (26/02/20 Pacientes em hemodiálise (Resultados acima deste ve Portaria N.82/GM em 03/01 (Método: Espectrofotometria de Absorção Atômica com C 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (23/02/20 (Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acoplado ao Espectr Até 1,0 µg/dL to a Mercúrio Orgânico: Maior que 5,0 µg/dL	022 09:21 rior a 10 - até 30 Jor, cons /2000 AN a Corretor 3 022 09:0
E Sangue Total) Tabela de Referê agem de Alumínio angue E Soro) Metodologia d agem de Mercúrio E Sangue Total) Tabela de Referê	ncia - Chumbo Sanguíne Metodologia des esenvolvida e validad	1,44 μg/dL o envolvida e validada pel L 3,50 μg/L da pelo laboratório d L 0,18 μg/dL úrio	(Méx Notas: Valor IBM lo laboratório de acordo iberado por: Sheila Vaso iberado por: Sheila Vaso (Méx Exposição Exposição e acordo com a RDC	(Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acoplado ao Espect Valor de Referência: até 40,0 µg/dL IBMP: até 60,0 µg/dL de Referência para pacientes não expostos. P: Indice Biológico Máximo Permitido (NR-7) com a RDC 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (26/02/20 Pacientes em hemodiálise (Resultados acima deste ve Portaria N.82/GM em 03/01 (Método: Espectrofotometria de Absorção Atômica con C 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (23/02/20 (Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acoplado ao Espectr Até 1,0 µg/dL to a Mercúrio Orgânico: Maior que 20,0 µg/dL	022 09:21 rior a 10 - até 30 alor, cons /2000 At a Corretor 2 022 09:0 erência A ômetro de
E Sangue Total) Tabela de Referê agem de Alumínio angue E Soro) Metodologia d agem de Mercúrio E Sangue Total) Tabela de Referê	ncia - Chumbo Sanguíne Metodologia des esenvolvida e validad	1,44 μg/dL o envolvida e validada pel L 3,50 μg/L da pelo laboratório d L 0,18 μg/dL úrio da pelo laboratorio d L	(Méx Notas: Valor IBM Io laboratório de acordo iberado por: Sheila Vaso (Méx Exposição Exposição e acordo com a RD0 iberado por: Sheila Vaso	(Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acoplado ao Espect Valor de Referência: até 40,0 µg/dL IBMP: até 60,0 µg/dL de Referência para pacientes não expostos. P: Indice Biológico Máximo Permitido (NR-7) com a RDC 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (26/02/20 Pacientes em hemodiálise (Resultados acima deste ve Portaria N.82/GM em 03/01 (Método: Espectrofotometria de Absorção Atômica com C 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (23/02/20 (Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acoplado ao Espectr Até 1,0 µg/dL to a Mercúrio Orgânico: Maior que 20,0 µg/dL 2 302 de 13/10/2005, Art. 5.5.5.1.	022 09:21 rior a 10 - até 30 alor, cons /2000 At a Corretor 2 022 09:0 erência A ômetro de
E Sangue Total) Tabela de Referê agem de Alumínio angue E Soro) Metodologia d agem de Mercúrio E Sangue Total) Tabela de Referê	ncia - Chumbo Sanguíne Metodologia des esenvolvida e validad	1,44 μg/dL o envolvida e validada pel L 3,50 μg/L da pelo laboratório d L 0,18 μg/dL úrio	(Méx Notas: Valor IBM Io laboratório de acordo iberado por: Sheila Vaso (Méx Exposição Exposição e acordo com a RD0 iberado por: Sheila Vaso	(Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acoplado ao Espect Valor de Referência: até 40,0 µg/dL IBMP: até 60,0 µg/dL de Referência para pacientes não expostos. P: Indice Biológico Máximo Permitido (NR-7) com a RDC 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (26/02/20 Pacientes em hemodiálise (Resultados acima deste ve Portaria N.82/GM em 03/01 (Método: Espectrofotometria de Absorção Atômica com C 302 de 13/10/2005, Art. 5.5.5.1. ques Leandro Argolo CRF-RJ : 4469 (23/02/20 (Vide Intervalo de Refe do: ICP-MS (Plasma Indutivamente Acoplado ao Espectr Até 1,0 µg/dL to a Mercúrio Orgânico: Maior que 20,0 µg/dL 2 302 de 13/10/2005, Art. 5.5.5.1.	022 09:21 rior a 10 - até 30 alor, cons /2000 At a Corretor 2 022 09:0 erência A ômetro de

156 **3. Discussion** 157

155

168

174

178 179 180

189 190

195

196

197

198

199

200

201

202

203

204

205

206

207 208

158 It can be concluded that there has been a significant improvement in microcirculatory parameters, an improvement in 159 the anti-inflammatory pattern, Ultra-sensitive C-Reactive Protein 0.09 mg/dL, but still with a slight alteration in the coagulation 160 cascade pattern and Erythrocyte Sedimentation Rate (ESR) 1st hour 30 mm, which still shows alterations, with Prothrombin 161 Time 12.70 s. There has been an improvement in the potassium bioavailability, stabilization of ferritin levels, consequently 162 improving oxygen transport and the systemic and peripheral microcirculatory systems, as well as liver function. Gamma-163 Glutamyl Transferase 9 U/L (low index), Total Bilirubin, Direct, and Indirect Bilirubin: Total Bilirubin 0.23 mg/dL, Urea 13 mg/dL 164 (normal range: 15 to 50 mg/dL), and C-Reactive Protein at the time of tooth extraction. The suspicion arises from the fact that the removal of some heavy metals, as well as dental materials and iron filings, altered the biological terrain, facilitating the 165 166 elimination processes dependent on the same metabolic pathways. After COVID, an attempt was made to eliminate 167 homotoxins and exotoxins.

Medical and nutritional follow-up of dietary patterns after endodontic and dental extraction interventions was suggested to determine the therapy's response in the patient's clinical condition. The patient is now undergoing therapeutic neural treatment and following a dietary plan. A food allergen test has already been conducted, including milk, eggs, egg yolk, nuts, and flour, all of which showed reactive results. However, the highest reactivity was observed with flour products and household dust, which were already indicated in the complete blood count and clinical history.

The multidisciplinary dental treatment aimed to reduce inflammatory processes, improve systemic microcirculation, enhance occlusion, distribute loads better, improve oral biocybernetics along with body axes, and attempt to minimize the histamine release triggers that led to autoimmune conditions.

4. Conclusions

Finally, the treatment objectives were successfully achieved. Significant results were obtained in the circulatory system, improvement in the excretion system, liver function, and glycemic control. In conclusion, the patient has experienced a significant improvement in quality of life and continues with treatment because some blood markers require long-term changes and cannot be addressed all at once due to considerable levels of heavy metal contaminants in the circulatory system. Further reduction in these levels has led to gradual improvement in the complete blood count and other markers.

187 Ethical considerations

Not applicable.

191 **Conflict of Interest** 192

193 The authors declare no conflicts of interest. 194

References

- R, Coeli C, Aguiar F, Vaisman M. Reference interval of thyroid stimulating hormone and free thyroxine in a reference population over 60 years old and in very old subjects (over 80 years): comparison to young subjectsThyroid Research 2013; 3:13-20. 2017
- 2. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid 2017;27(3):315-90.
 - 3. Morais NAOS, Assis ASA, Corcino CM, Saraiva DA, Berbara TMBL, Ventura CDD, Vaisman M, Teixeira PFS. Recent recommendations from ATA guidelines to define the upper reference range for serum TSH in the first trimester match reference ranges for pregnant women in Rio de Janeiro Arch Endocrinol Metab. 2018; 62(4): 386-9
 - 4. Burtis, CA; Ashwood, ER; Bruns, DE. Tietz Textbook of Clinical Chemistry and Molecular Diagnosis. 40 Ed. Saint Louis: Elsevier Saunders, 2006
- 5. Soldin, SJ; Brugnara, C; Wong, EC, Soldin, OP. Pediatric Reference Intervals. 7a. Ed. Washington DC: AACCPress, 2011.